We are live on
!
Find out more
Alkeon Capital Management Portfolio holdings
AUM
$59.5B
1-Year Est. Return
51.63%
This Fund
S&P 500
This Quarter
Est. Return
+6.23%
1 Year Est. Return
+51.63%
3 Year Est. Return
+162.63%
5 Year Est. Return
+168.42%
10 Year Est. Return
+1,374.92%
AUM
$25.9B
AUM Growth
-$5.02B
(-16%)
Cap. Flow
-$1,000M
Cap. Flow
% of AUM
-3.86%
Top 10 Holdings %
Top 10 Hldgs %
43.79%
Holding
139
New
6
Increased
35
Reduced
74
Closed
12
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Meta Platforms (Facebook)
META
|
+$150M |
| 2 |
BILL Holdings
BILL
|
+$145M |
| 3 |
Lowe's Companies
LOW
|
+$87.7M |
| 4 |
Uber
UBER
|
+$62.9M |
| 5 |
Baidu
BIDU
|
+$56.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
KLA
KLAC
|
+$195M |
| 2 |
Alphabet (Google) Class A
GOOGL
|
+$161M |
| 3 |
AYX
Alteryx Inc
AYX
|
+$126M |
| 4 |
Atlassian
TEAM
|
+$121M |
| 5 |
Lam Research
LRCX
|
+$98M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.71% |
| 2 | Consumer Discretionary | 10.65% |
| 3 | Financials | 6.39% |
| 4 | Communication Services | 6.11% |
| 5 | Healthcare | 2.77% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
KLRS
101
Kalaris Therapeutics
KLRS
$94.7M
| $23.6M | 0.09% |
200,222
-13,826
| -6% | -$2.35M |
|
102
FIVE9
FIVN
$2.5B
| $23.1M | 0.09% |
339,836
-636,783
| -65% | -$40M |
|
103
dLocal
DLO
$4.23B
| $22.2M | 0.09% |
1,427,890
-1,081,323
| -43% | -$19M |
|
104
JFrog
FROG
$10.4B
| $21.7M | 0.08% |
1,016,208
-154,773
| -13% | -$3.52M |
|
105
Marqeta
MQ
$1.65B
| $21.6M | 0.08% |
884,243
-137,154
| -13% | -$3.74M |
|
106
Stem
STEM
$50.8M
| $19.7M | 0.08% |
109,923
-17,125
| -13% | -$4.12M |
|
|
BPMC
107
DELISTED
Blueprint Medicines
BPMC
| $18.7M | 0.07% |
426,268
-693,144
| -62% | -$33.2M |
|
108
BioCryst Pharmaceuticals
BCRX
$2.46B
| $17.1M | 0.07% |
1,485,817
+20,532
| +1% | +$256K |
|
|
IGMS
109
DELISTED
IGM Biosciences
IGMS
| $14.2M | 0.05% |
833,241
-128,372
| -13% | -$2.57M |
|
110
Oric Pharmaceuticals
ORIC
$1.4B
| $14.1M | 0.05% |
2,399,252
+292,284
| +14% | +$987K |
|
111
PMV Pharmaceuticals
PMVP
$63.5M
| $12.1M | 0.05% |
1,385,267
-131,979
| -9% | -$1.41M |
|
112
Procore
PCOR
$8.73B
| $9.26M | 0.04% |
196,375
-30,554
| -13% | -$1.56M |
|
113
Apple
AAPL
$4.48T
| $7.36M | 0.03% |
56,627
| – | – |
|
114
BJs Wholesale Club
BJ
$12.2B
| $7.28M | 0.03% |
110,000
| – | – |
|
|
ALTR
115
DELISTED
Altair Engineering Inc
ALTR
| $6.82M | 0.03% |
150,055
-23,157
| -13% | -$1.08M |
|
116
Caribou Biosciences
CRBU
$164M
| $6.65M | 0.03% |
1,058,603
-163,488
| -13% | -$1.45M |
|
117
Sony
SONY
$140B
| $4.2M | 0.02% |
275,000
| – | – |
|
118
American Express
AXP
$228B
| $3.69M | 0.01% |
25,000
-369,419
| -94% | -$54.7M |
|
|
ATVI
119
DELISTED
Activision Blizzard
ATVI
| $1.95M | 0.01% |
25,495
| – | – |
|
|
MREO
120
Mereo BioPharma
MREO
$46.3M
| $1.6M | 0.01% |
2,135,600
| – | – |
|
|
121
CALL
Apple
AAPL
$4.48T
| – | – |
-4,000,000
| Closed | -$553M |
|
122
CALL
Coinbase
COIN
$39.7B
| – | – |
-540,000
| Closed | -$34.8M |
|
123
CALL
Salesforce
CRM
$159B
| – | – |
-980,000
| Closed | -$141M |
|
|
DOCU
124
CALL
DocuSign
DOCU
$11.4B
| – | – |
-2,000,000
| Closed | -$107M |
|
|
125
CALL
Alphabet (Google) Class A
GOOGL
$4.37T
| – | – |
-1,000,000
| Closed | -$95.7M |
|
Similar funds
QCM
NAMI
Alkeon Capital Management's Q4 2022 Portfolio in Review
As of Q4 2022, Alkeon Capital Management held 139 positions worth $25.9B, down 16% from $30.9B the previous quarter. Its ten largest holdings account for 44% of the portfolio.
Alkeon Capital Management withdrew a net $1,000M in Q4 2022, closing 12 positions and reducing 74 holdings. Its most notable exit was Alteryx Inc, an estimated $126M position sold in full.
By sector, the portfolio is most concentrated in Technology at 21% of assets, up from 20% a quarter earlier, followed by Consumer Discretionary and Financials.
Against the trend, Alkeon Capital Management opened a new position in DICE Therapeutics, Inc. Common Stock worth $32.4M.
- Alkeon Capital Management's largest Q4 2022 buy was DICE Therapeutics, Inc. Common Stock: 1,038,125 shares worth $32.4M.
- Alkeon Capital Management added most to Meta Platforms (Facebook) in Q4 2022, an estimated $150M increase.
- Alkeon Capital Management's biggest Q4 2022 reduction was KLA, cutting an estimated $195M.
- Alkeon Capital Management fully exited Alteryx Inc in Q4 2022, selling an estimated $126M.
- Alkeon Capital Management's ten largest holdings make up 44% of its $25.9B portfolio in Q4 2022.
- Alkeon Capital Management opened 6 new positions and closed 12 in Q4 2022.
- Alkeon Capital Management's portfolio value fell 16% quarter-over-quarter to $25.9B.
Based on Alkeon Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.